Literature DB >> 11127475

An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes.

R H Böger1, S M Bode-Böger, P S Tsao, P S Lin, J R Chan, J P Cooke.   

Abstract

OBJECTIVES: We sought to determine whether asymmetric dimethylarginine (ADMA) inhibits nitric oxide (NO) elaboration in cultured human endothelial cells and whether this is associated with the activation of oxidant-sensitive signaling mediating endothelial adhesiveness for monocytes.
BACKGROUND: Endothelial NO elaboration is impaired in hypercholesterolemia and atherosclerosis, which may be due to elevated concentrations of ADMA, an endogenous inhibitor of NO synthase.
METHODS: Human umbilical vein endothelial cells (ECV 304) and human monocytoid cells (THP-1) were studied in a functional binding assay. Nitric oxide and superoxide anion (O2-) were measured by chemiluminescence; ADMA by high pressure liquid chromatography; monocyte chemotactic protein-1 (MCP-1) by ELISA and NF-KB by electromobility gel shift assay.
RESULTS: Incubation of endothelial cells with ADMA (0.1 microM to 100 microM) inhibited NO formation, which was reversed by coincubation with L-arginine (1 mM). The biologically inactive stereoisomer symmetric dimethylarginine did not inhibit NO release. Asymmetric dimethylarginine (10 microM) or native low-density lipoprotein cholesterol (100 mg/dL) increased endothelial O2- to the same degree. Asymmetric dimethylarginine also stimulated MCP-1 formation by endothelial cells. This effect was paralleled by activation of the redox-sensitive transcription factor NF-KB. Preincubation of endothelial cells with ADMA increased the adhesiveness of endothelial cells for THP-1 cells in a concentration-dependent manner. Asymmetric dimethylarginine-induced monocyte binding was diminished by L-arginine or by a neutralizing anti-MCP-1 antibody.
CONCLUSIONS: We concluded that the endogenous NO synthase inhibitor ADMA is synthesized in human endothelial cells. Asymmetric dimethylarginine increases endothelial oxidative stress and potentiates monocyte binding. Asymmetric dimethylarginine may be an endogenous proatherogenic molecule.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127475     DOI: 10.1016/s0735-1097(00)01013-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  51 in total

Review 1.  Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.

Authors:  Xiaohong Liu; Xin Xu; Ruru Shang; Yingjie Chen
Journal:  Nitric Oxide       Date:  2018-06-19       Impact factor: 4.427

2.  Asymmetric dimethylarginine is associated with high-sensitivity C-reactive protein and early carotid atherosclerosis in women with previous gestational diabetes mellitus.

Authors:  Wei Xia; Dajiang Li; Chunquan Zhang; Li Xu; Wenliang Xu; Yibing Shao
Journal:  Endocrine       Date:  2014-06-25       Impact factor: 3.633

Review 3.  Effect of asymmetric dimethylarginine (ADMA) on heart failure development.

Authors:  Xiaoyu Liu; Lei Hou; Dachun Xu; Angela Chen; Liuqing Yang; Yan Zhuang; Yawei Xu; John T Fassett; Yingjie Chen
Journal:  Nitric Oxide       Date:  2016-02-24       Impact factor: 4.427

Review 4.  The role of asymmetric and symmetric dimethylarginines in renal disease.

Authors:  Edzard Schwedhelm; Rainer H Böger
Journal:  Nat Rev Nephrol       Date:  2011-03-29       Impact factor: 28.314

5.  Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunction.

Authors:  Neetu Sud; Sandra M Wells; Shruti Sharma; Dean A Wiseman; Jason Wilham; Stephen M Black
Journal:  Am J Physiol Cell Physiol       Date:  2008-04-02       Impact factor: 4.249

6.  Mechanisms of nitric oxide synthase uncoupling in endotoxin-induced acute lung injury: role of asymmetric dimethylarginine.

Authors:  Shruti Sharma; Anita Smith; Sanjiv Kumar; Saurabh Aggarwal; Imran Rehmani; Connie Snead; Cynthia Harmon; Jeffery Fineman; David Fulton; John D Catravas; Stephen M Black
Journal:  Vascul Pharmacol       Date:  2009-12-03       Impact factor: 5.773

Review 7.  Oxidative stress as a mediator of cardiovascular disease.

Authors:  Maqsood M Elahi; Yu Xiang Kong; Bashir M Matata
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

Review 8.  Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis.

Authors:  Paloma Lluch; Gloria Segarra; Pascual Medina
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

9.  Elevated asymmetric dimethylarginine alters lung function and induces collagen deposition in mice.

Authors:  Sandra M Wells; Mary C Buford; Christopher T Migliaccio; Andrij Holian
Journal:  Am J Respir Cell Mol Biol       Date:  2008-08-14       Impact factor: 6.914

10.  Angiotensin II Blockade and Total Cardiovascular Risk : Beyond Blood Pressure Reduction.

Authors:  Francesco Cipollone; Sara Di Fabio; Marco Bucci; Giancarlo Cicolini; Andrea Mezzetti
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.